DiaMedica Therapeutics Inc. (DMAC)
NASDAQ (CM) NASDAQ (CM) Primary 
DiaMedica Therapeutics Inc. (DMAC) Q4 2024 Earnings Call Transcript
DiaMedica Therapeutics Inc. (NASDAQ:DMAC ) Q4 2024 Earnings Conference Call March 18, 2025 8:00 AM ET Company Participants Rick Pauls - President and CEO Lorianne Masuoka - CMO Scott Kellen - CFO Conference Call Participants Thomas Flaten - Lake Street Chase Knickerbocker - Craig-Hallum Matthew Caufield - H.C. Wainwright Operator Good morning, ladies and gentlemen, and welcome to the DiaMedica Therapeutics Full Year 2024 Conference Call.
DiaMedica Therapeutics Inc. (DMAC) Q3 2024 Earnings Call Transcript
DiaMedica Therapeutics Inc. (NASDAQ:DMAC ) Q3 2024 Earnings Conference Call November 14, 2024 8:00 AM ET Company Participants Rick Pauls - President, Chief Executive Officer & Director Scott Kellen - Chief Financial Officer & Company Secretary Lorianne Masuoka - Chief Medical Officer Conference Call Participants Thomas Flaten - Lake Street Chase Knickerbocker - Craig-Hallum Matthew Caufield - H.C. Wainwright Operator Good morning ladies and gentlemen and welcome to the DiaMedica Therapeutics Third Quarter 2024 Conference Call.
Best Momentum Stocks to Buy for October 14th
IAG, DMAC and HIVE made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on October 14, 2024.
Are Medical Stocks Lagging DiaMedica Therapeutics (DMAC) This Year?
Here is how DiaMedica Therapeutics, Inc. (DMAC) and Elutia Inc. (ELUT) have performed compared to their sector so far this year.
DiaMedica: Early 2025 Interim Futility Analysis Could Be A Major Inflection Point
An interim futility analysis by the DSMB of DM199 for patients with AIS in the phase 2/3 ReMEDy2 trial is expected by Q1 of 2025. The global acute ischemic stroke therapeutics market size is expected to be worth $14 billion by 2032. Proof-of-concept data from a phase 2 study, using DM199 for the treatment of women with pregnancy complications, is expected 1st half of 2025.
